AnaptysBio - Overview
About
Overview
Strategy
Management
Board of Directors
Research and Development Committee
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Pipeline
Imsidolimab (ANB019):
Anti-IL-36R
DEVELOPMENT STAGE & ANTICIPATED MILESTONES
THERAPEUTIC
INDICATION
COMMERCIAL
RIGHTS
ANTIBODY
PROGRAM
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Phase 1 Data
Presented at
EAACI 2018
GALLOP: Phase 2 Data Presented At
EADV Congress on October 2nd 2021
Top-Line Data
Anticipated Q4 2023
HARP: Topline Data Anticipated H2 2022
Generalized Pustular
Psoriasis
ANB032: Anti-BTLA Agonist
Inflammatory Diseases
Hidradenitis
Suppurativa
Phase 1 Top-Line
Data Anounced
April 2022
Rosnilimab (ANB030):
Anti-PD-1 Agonist
Alopecia Areata
Phase 1 Top-Line
Data Announced
Nov 2021
AZURE: Phase 2 Initiated Q4 2021
IND Filing of Phase 2 Trial
in H2 2022